Solving the Antidepressant Efficacy Question: Effect Sizes in Major Depressive Disorder

被引:50
|
作者
Voehringer, Paul A. [1 ,2 ]
Ghaemi, S. Nassir [3 ]
机构
[1] Tufts Med Ctr, Dept Psychiat, Mood Disorders Program, Boston, MA 02111 USA
[2] Univ Chile, Fac Med, Hosp Clin, Santiago 7, Chile
[3] Tufts Univ, Sch Med, Boston, MA 02111 USA
关键词
antidepressants; effect size; meta-analysis; randomized clinical trials; STAR-ASTERISK-D; MAINTENANCE TREATMENT; BIPOLAR DISORDER; VENLAFAXINE; OUTCOMES; DISCONTINUATION; SEVERITY; PREVENT;
D O I
10.1016/j.clinthera.2011.11.019
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Numerous reviews and meta-analyses of the antidepressant literature in major depressive disorders (MDD), both acute and maintenance, have been published, some claiming that antidepressants are mostly ineffective and others that they are mostly effective, in either acute or maintenance treatment. Objective: The aims of this study were to review and critique the latest and most notable antidepressant MDD studies and to conduct our own reanalysis of the US Food and Drug Administration database studies specifically analyzed by Kirsch et al. Methods: We gathered effect estimates of each MDD study. In our reanalysis of the acute depression studies, we corrected analyses for a statistical floor effect so that relative (instead of absolute) effect size differences were calculated. We also critiqued a recent meta-analysis of the maintenance treatment literature. Results: Our reanalysis showed that antidepressant benefit is seen not only in severe depression but also in moderate depression and confirmed a lack of benefit for antidepressants over placebo in mild depression. Relative antidepressant versus placebo benefit increased linearly from 5% in mild depression to 12% in moderate depression to 16% in severe depression. The claim that antidepressants are completely ineffective, or even harmful, in maintenance treatment studies involves unawareness of the enriched design effect, which, in that analysis, was used to analyze placebo efficacy. The same problem exists for the standard interpretation of those studies, although they do not prove antidepressant efficacy either, since they are biased in favor of antidepressants. Conclusions: In sum, we conclude that antidepressants are effective in acute depressive episodes that are moderate to severe but are not effective in mild depression. Except for the mildest depressive episodes, correction for the statistical floor effect proves that antidepressants are effective acutely. These considerations only apply to acute depression, however. For maintenance, the long-term efficacy of antidepressants is unproven, but the data do not support the conclusion that they are harmful. (Clin Ther. 2011;33:B49-B61) (C) 2011 Elsevier HS Journals, Inc. All rights reserved.
引用
收藏
页码:B49 / B61
页数:13
相关论文
共 50 条
  • [1] Understanding the Antidepressant Debate in the Treatment of Major Depressive Disorder
    Naudet, Florian
    Boussageon, Remy
    Palpacuer, Clement
    Gallet, Laurent
    Reymann, Jean-Michel
    Falissard, Bruno
    THERAPIE, 2015, 70 (04): : 321 - 327
  • [2] Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder
    Hunter, Aimee M.
    Muthen, Bengt O.
    Cook, Ian A.
    Leuchter, Andrew F.
    JOURNAL OF PSYCHIATRIC RESEARCH, 2010, 44 (02) : 90 - 98
  • [3] Evaluating the efficacy and moderators of algorithm-guided antidepressant treatments of major depressive disorder
    Zhang, Huifeng
    Wu, Zhiguo
    Cao, Lan
    Su, Yousong
    Wang, Fan
    Hong, Wu
    Cai, Yiyun
    Peng, Daihui
    Fang, Yiru
    JOURNAL OF AFFECTIVE DISORDERS, 2022, 297 : 68 - 75
  • [4] The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder
    Reed, Carol R.
    Kajdasz, Daniel K.
    Whalen, Heidi
    Athanasiou, Maria C.
    Gallipoli, Susan
    Thase, Michael E.
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (01) : 27 - 39
  • [5] Functional connectivity of the hippocampus in predicting early antidepressant efficacy in patients with major depressive disorder
    Xiao, Hongqi
    Yuan, Minlan
    Li, Hailong
    Li, Shiyi
    Du, Yang
    Wang, Mei
    Zhu, Hongru
    Zhang, Wei
    Qiu, Changjian
    Huang, Xiaoqi
    JOURNAL OF AFFECTIVE DISORDERS, 2021, 291 : 315 - 321
  • [6] Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder
    Kohler-Forsberg, Ole
    Larsen, Erik Roj
    Buttenschon, Henriette N.
    Rietschel, Marcella
    Hauser, Joanna
    Souery, Daniel
    Maier, Wolfgang
    Farmer, Anne
    McGuffin, Peter
    Aitchison, Katherine J.
    Uher, Rudolf
    Mors, Ole
    BRITISH JOURNAL OF PSYCHIATRY, 2019, 215 (02) : 494 - 501
  • [7] Analysis of the Deleterious Single-Nucleotide Polymorphisms Associated With Antidepressant Efficacy in Major Depressive Disorder
    Xin, Juncai
    Yuan, Meng
    Peng, Yonglin
    Wang, Ju
    FRONTIERS IN PSYCHIATRY, 2020, 11
  • [8] Association of the TLR4 gene with depressive symptoms and antidepressant efficacy in major depressive disorder
    Wang, Jizhi
    Yang, Chunxia
    Liu, Zhifen
    Li, Xinxin
    Liu, Min
    Wang, Yanfang
    Zhang, Kerang
    Sun, Ning
    NEUROSCIENCE LETTERS, 2020, 736
  • [9] Antidepressant dose reduction and the risk of relapse in major depressive disorder
    Papakostas, George I.
    Perlis, Roy H.
    Seifert, Cheryl
    Fava, Maurizio
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2007, 76 (05) : 266 - 270
  • [10] Has the symptom severity inclusion requirement narrowed the definition of major depressive disorder in antidepressant efficacy trials?
    Zimmerman, Mark
    Walsh, Emily
    Chelminski, Iwona
    Dalrymple, Kristy
    JOURNAL OF AFFECTIVE DISORDERS, 2017, 211 : 60 - 64